Xeomin®
Wilson Disease
The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Wilson Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ZINC ACETATE Nobelpharma | Phase 4 | BBB |
Trientine Excelsior | Phase 3 | BB |
Teta 4Hcl Orphalan | Phase 3 | BB |
Alxn1840 Alexion Pharmaceuticals, Inc. | Phase 3 | BB |
Tetrathiomolybdate National Center for Research Resources (NCRR) | Phase 3 | B |
View all 12 →
Same molecule, other indications
Xeomin® is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →